Clinical trials: Antiviral Agents
HIV Infections
Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents
Dolutegravir (DTG) is an HIV drug in the integrase inhibitor drug class. This study evaluated the pharmacokinetics (PK), safety, tolerability of and immune response to DTG when used concurrently with optimized background therapy…
- Trial name
- NCT01302847
- Testing
- DTG film-coated tablets, DTG granules for suspension, DTG dispersible tablets
- Where
- 33 sites in United States, Botswana and 6 more
- Volunteers
- 181 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Hepatitis B
Maintaining Antiviral Efficacy After Switching to Generic Entecavir 1 mg for Chronic Hepatitis B
Entecavir 1 mg is commonly used in patients with chronic hepatitis B (CHB) patients with previous antiviral resistance. This study evaluates the efficacy and safety of switching to generic entecavir 1 mg (Baracle®, Dong-A Science…
- Trial name
- NCT04069858
- Testing
- Switching to Generic Entecavir (Baracle®)
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Korea University
HIV Infection, Hepatitis C
HCV/HIV Coinfection: Antiviral Therapy and Fibrosis
The chief purpose of this research is to understand how antiretroviral therapy (ART) affects progression of liver disease in persons co-infected with HIV and hepatitis C virus (HCV).
- Trial name
- NCT01423643
- Where
- United States
- Volunteers
- 1,250 people
- Sponsor
- Johns Hopkins University
Influenza, Severe Acute Respiratory Distress Syndrome
Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study
This study will examine the safety of an experimental medication called Poly-ICLC, developed for preventing or reducing the severity of infections from influenza and other viruses acquired through the nose, mouth and lungs.
- Conditions
- Influenza, Severe Acute Respiratory Distress Syndrome, Smallpox, Ebola
- Trial name
- NCT00646152
- Testing
- Poly-ICLC
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Hepatitis c
Side Effects After Direct-acting Antiviral Treatment
The objective of this study was to assess the incidence of side effects after direct-acting antiviral therapy in patients with chronic hepatitis C virus infection.
- Trial name
- EFINO-C (NCT03346941)
- Testing
- DAA treatment
- Where
- France
- Volunteers
- 95 people
- Sponsor
- Hospices Civils de Lyon
HIV-1-infection
Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children
The goal of this clinical study is to learn more about the study drug, lenacapavir (LEN). The study will assess the safety, tolerability, and efficacy of long-acting LEN when combined with other medicines in adolescents and…
- Trial name
- NCT06749054
- Testing
- Oral Lenacapavir, Subcutaneous Lenacapavir, Optimized Background Regimen (OBR)
- Where
- 9 sites in United States, South Africa
- Volunteers
- 12 people
- Sponsor
- Gilead Sciences
Beta-Thalassemia, Hepatitis C
Hyalornic Acid Level in β-Thalassemic Children Treated for Hepatitis C Virus
Patients with transfusion dependent Beta Thalassemia suffer from a high incidence of Hepatitis C infection especially in developed countries as Egypt.
- Trial name
- NCT03961828
- Testing
- Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni]
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Tanta University
Chronic Hepatitis B
Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients
This Phase 1b trial will assess the dose-related safety and PK profile of different doses of NVR 3-778 in patients with chronic hepatitis B.
- Trial name
- NCT02401737
- Testing
- NVR 3-778, Pegasys
- Where
- 10 sites in United States, China and 3 more
- Volunteers
- 58 people
- Sponsor
- Novira Therapeutics, Inc.
Hepatitis C
EBR/GZR for HCV-1b Patients Receiving Hemodialysis
Hepatitis C virus (HCV) infection is common in patients receiving hemodialysis. The uptake of antiviral therapy for these patients is limited in the era of interferon (IFN) plus ribavirin (RBV), probably because the sustained…
- Trial name
- NCT03420300
- Testing
- EBR/GZR
- Where
- 6 sites in Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Pharmacological Action
Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.
There is no specific antiviral treatment recommended for COVID-19, and no vaccine is currently available. Baricitinib, an anti-Janus kinase inhibitor (anti-JAK) acting against JAK1 and JAK2.
- Trial name
- BARI-COVID (NCT04320277)
- Testing
- Baricitinib
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Hospital of Prato
Hepatitis C
Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects
The primary purpose of this study is to assess the effect of the Daclatasvir/Asunaprevir/BMS-791325 fixed dose combination (FDC) tablet on the pharmacokinetics of the cocktail CYP and transporter probe substrates and to assess…
- Trial name
- NCT02045966
- Testing
- Cocktail, DCV 3DAA FDC, BMS-791325
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy, HIV Infection
Safety and Anti-HIV Activity of Capravirine Alone and in Combination With Other Anti-HIV Drugs
This 2-part study will test the safety and anti-HIV activity of capravirine alone, and the safety, anti-HIV activity, and drug interactions of capravirine combined with other anti-HIV drugs.
- Trial name
- NCT00005673
- Testing
- Capravirine
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B, Chronic
A Study of Treatment With RO6864018 in Virologically Suppressed Participants With Chronic Hepatitis B Virus (HBV) Infection
This randomized, multicenter, partially double-blind, placebo-controlled study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antiviral effects of treatment with RO6864018 in…
- Trial name
- NCT02391805
- Testing
- Entecavir, RO6864018, Tenofovir
- Where
- 14 sites in Hong Kong, Malaysia and 4 more
- Volunteers
- 31 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C Virus Infection
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection
The primary objective of the study is to evaluate the safety and tolerability of voxilaprevir (formerly GS-9857) alone or with sofosbuvir (SOF)/velpatasvir (VEL) fixed dose combination (FDC) and antiviral activity of voxilaprevir…
- Trial name
- NCT02185794
- Testing
- Voxilaprevir, SOF/VEL
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 101 people
- Sponsor
- Gilead Sciences
Hepatitis C, HIV
Control and Elimination Within Australia of Hepatitis C From People Living With HIV
The purpose of this study is to evaluate the feasibility of rapid scale-up of new hepatitis C (HCV) treatments, known as interferon-free Direct Acting Antiviral (DAA) drugs, and impact on the proportion of people with HCV within…
- Conditions
- Hepatitis C, HIV, HIV-HCV Coinfection
- Trial name
- CEASE (NCT02102451)
- Where
- 18 sites in Australia
- Volunteers
- 492 people
- Sponsor
- Kirby Institute
Human Immunodeficiency Virus 1
A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children
The purpose of this study is to evaluate the pharmacokinetics (what the body does to the medication), safety and antiviral activity to support dose recommendations by body weight of darunavir with low-dose ritonavir (DRV/rtv), in…
- Trial name
- NCT00919854
- Testing
- Darunavir, Ritonavir
- Where
- 8 sites in Argentina, Brazil and 3 more
- Volunteers
- 27 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Infection, Human Immunodeficiency Virus I
48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection
This is a 48-week study to collect information on the safety and activity of an investigational medicine in patients, ages 2 to 18 years old, with HIV infection .
- Trial name
- NCT00089583
- Testing
- LEXIVA (GW433908), Ritonavir
- Where
- 39 sites in United States, Belgium and 5 more
- Volunteers
- 110 people
- Sponsor
- ViiV Healthcare
Chronic Hepatitis B
Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents
Current treatment guidelines indicate that oral antiviral agents for HBeAg-positive chronic hepatitis B virus infection (CHB) can be stopped if the patient has undergone HBeAg seroconversion with HBV-DNA loss measured at two…
- Trial name
- NCT02337127
- Testing
- Lamivudine
- Where
- Taiwan
- Volunteers
- 500 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Chronic Hepatitis C
Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection
This study was to assess whether sofosbuvir in combination with ribavirin (RBV) and pegylated interferon alfa 2a (PEG) administered for 12 weeks is safe and effective in patients with hepatitis C virus (HCV) genotypes 1, 4, 5 …
- Trial name
- NEUTRINO (NCT01641640)
- Testing
- Sofosbuvir, RBV, PEG
- Where
- 56 sites in United States, Puerto Rico
- Volunteers
- 328 people
- Sponsor
- Gilead Sciences
HEPATITIS C, Virus, Human Immunodeficiency
Antiviral Pharmacology and Adherence in Drug Users
Approximately one half of all Americans living with Hepatitis C virus (HCV) are drug users, yet they are the least likely to receive HCV treatment.
- Trial name
- NCT02573376
- Testing
- Directly Observed Therapy, Wirelessly Observed Therapy
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- University of Colorado, Denver
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.